Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
Published Online: 2024-11-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alastair Mathewson•Alfiya Nesterova•Bistra Kirova•Christopher J Morrow•Claudio Zamagni•Delphine Lissa•Denys Pominchuk•Ekaterine Arkania•Erika Hamilton•Frédéric Forget•Gia Nemsadze•Hannelore Denys•Justin P O Lindemann•Mafalda Oliveira•Maxine Ajimi•Patrick Neven•Ruaan van Zyl•Tamar Melkadze•Teresa Klinowska•Timur Andabekov•Vladimir Vladimirov•Yaroslav Kulyaba•Yevhen Hotko•Zbigniew Nowecki•Zsolt Horvath•Zuzana Traugottova
